Teva Pharmaceutical Inds LTD (TEVA) Shareholder Mivtachim The Workers Social Insurance Fund LTD Decreased Holding as Market Valuation Rose

September 8, 2018 - By Pearl Odom

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Logo

Mivtachim The Workers Social Insurance Fund Ltd decreased its stake in Teva Pharmaceutical Inds Ltd (TEVA) by 28.57% based on its latest 2018Q1 regulatory filing with the SEC. Mivtachim The Workers Social Insurance Fund Ltd sold 280,000 shares as the company’s stock rose 10.90% while stock markets declined. The institutional investor held 700,000 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $11.96 million, down from 980,000 at the end of the previous reported quarter. Mivtachim The Workers Social Insurance Fund Ltd who had been investing in Teva Pharmaceutical Inds Ltd for a number of months, seems to be less bullish one the $21.89B market cap company. The stock decreased 1.15% or $0.25 during the last trading session, reaching $21.5. About 9.73M shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 22.74% since September 8, 2017 and is downtrending. It has underperformed by 35.31% the S&P500.

Mivtachim The Workers Social Insurance Fund Ltd, which manages about $1.42 billion US Long portfolio, upped its stake in Financial Select Sector Spdr (XLF) by 1.00M shares to 3.24M shares, valued at $89.43 million in 2018Q1, according to the filing.

Analysts await Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report earnings on November, 1. They expect $0.54 EPS, down 43.16 % or $0.41 from last year’s $0.95 per share. TEVA’s profit will be $549.87M for 9.95 P/E if the $0.54 EPS becomes a reality. After $0.75 actual EPS reported by Teva Pharmaceutical Industries Limited for the previous quarter, Wall Street now forecasts -28.00 % negative EPS growth.

More notable recent Teva Pharmaceutical Industries Limited (NYSE:TEVA) news were published by: Fool.com which released: “Why Symantec, Teva Pharmaceutical Industries, and Century Aluminum Jumped Today” on August 16, 2018, also Benzinga.com with their article: “Teva Wins FDA Approval For Generic Epinephrine” published on August 16, 2018, Schaeffersresearch.com published: “TEVA Stock Extends Slide After Bear Note” on September 07, 2018. More interesting news about Teva Pharmaceutical Industries Limited (NYSE:TEVA) were released by: Seekingalpha.com and their article: “FDA OKs Teva’s opioid dependence med Cassipa” published on September 07, 2018 as well as Fool.com‘s news article titled: “3 Growth Stocks at Deep-Value Prices” with publication date: September 03, 2018.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage

Among 12 analysts covering Teva Pharma (NYSE:TEVA), 3 have Buy rating, 1 Sell and 8 Hold. Therefore 25% are positive. Teva Pharma had 17 analyst reports since March 13, 2018 according to SRatingsIntel. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Equal-Weight” rating given on Friday, August 3 by Morgan Stanley. Guggenheim maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Tuesday, March 13 with “Hold” rating. Wells Fargo upgraded the stock to “Market Perform” rating in Monday, June 18 report. On Friday, April 20 the stock rating was maintained by Mizuho with “Buy”. The firm has “Buy” rating given on Thursday, May 31 by Citigroup. Wells Fargo maintained it with “Sell” rating and $16.5000 target in Thursday, May 3 report. Goldman Sachs upgraded Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Monday, June 25 to “Buy” rating. The company was maintained on Monday, August 6 by Barclays Capital. The rating was maintained by Morgan Stanley on Monday, May 7 with “Equal-Weight”. The stock has “Neutral” rating by Cantor Fitzgerald on Monday, July 16.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.